New analysis shows NHS trusts are failing to hit a key waiting times pledge for seeing and treating people with cancer (PA) ...
"People often think that as palliative care doctors we only see people who are very old," Dr. Kerith Whittigan said ...
The NHS has failed to meet a longstanding target that sees 85% of patients start treatment within 62 days of an urgent cancer ...
Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...
A Norfolk hospital has been ranked as one of the worst in England for cancer waiting times. Just 54.2% of patients began treatment within 62 days of their referral to the Queen Elizabeth Hospital (QEH ...
Breast cancer cases in India have increased sharply since 1990 due to lifestyle changes and urbanisation. An expert stresses ...
Cancer patients waiting over 104 days for treatment as data shows the NHS trusts failing to meet crucial target - The new analysis of NHS England figures shows just three of 119 acute trusts with comp ...
The anti-parasitic drug became a household name during the COVID-19 pandemic, and it is now being embraced as an alternative ...
York and Scarborough Teaching Hospitals NHS Foundation Trust has apologised to patients after missing a major cancer target for another year.
After getting engaged, the only words journalist Mrinali Dhembla expected to hear were “I do.” Instead, she was told, “You have cancer.” “When I first heard the words, ‘You have cancer,’ I was ...
As nonprofit-governed Servier continues to make gains with its IDH-mutant glioma med Voranigo, the drugmaker is wading deeper into the rare oncology arena with a new M&A play. | Servier on Friday ...
Dealbreaker on MSN
Servier boosts presence in rare cancers with $2.5B acquisition of Day One Biopharma
Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in children.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results